Prevention of thromboembolic complications in patients with rheumatic heart disease
Summary. Summary. The aim was to investigate the frequency of use and the effectiveness of the control of anticoagulation in patients with atrial fibrillation (AF) and rheumatic mitral klapana. Material and methods. In a retrospective study analyzed the medical records of 23 patients with atrial fibrillation and rheumatic mitral valve aged ≥18 years. The results. In the group of aspirin therapy the risk of ischemic stroke/transient ischemic attack (TIA) was 2.1 times higher (odds ratio [OR]=2.11 [95% CI: 1.61–3.37]) compared with the group receiving warfarin TTR <55% in the group aspirin risk of adverse events was similar on warfarin group TTR <55%, but 21% lower than in the group without antithrombotic therapy. Major bleeding events were lower in the group receiving aspirin compared with warfarin TTR≥55% (OR=1.52 [1.23–1.83]) or warfarin group with TTR <55% (OR=4.01 [1.21–1.85]). Conclusion. Aspirin therapy in patients with atrial fibrillation and rheumatic mitral valve showed no warning of the worst AI/TIA than the group receiving warfarin with an INR labile (TTR <55%), with less of bleeding.
Leave a comment